Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Change in Accured Expenses for 6 consecutive years, with -$331000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 280.46% to -$331000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $569000.0, a 264.45% increase, with the full-year FY2024 number at -$39000.0, down 195.12% from a year prior.
  • Change in Accured Expenses was -$331000.0 for Q3 2025 at Vivos Therapeutics, down from $248000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $728000.0 in Q1 2021 to a low of -$1.2 million in Q4 2022.
  • A 5-year average of $25947.4 and a median of $31000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 787.88% in 2024, then skyrocketed 1795.24% in 2025.
  • Vivos Therapeutics' Change in Accured Expenses stood at $320000.0 in 2021, then crashed by 475.62% to -$1.2 million in 2022, then skyrocketed by 95.59% to -$53000.0 in 2023, then soared by 579.25% to $254000.0 in 2024, then tumbled by 230.31% to -$331000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Change in Accured Expenses are -$331000.0 (Q3 2025), $248000.0 (Q2 2025), and $398000.0 (Q1 2025).